Search for: "United States v. Holman" Results 41 - 60 of 66
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
10 Oct 2008, 11:32 am
You can separately subscribe to the Pharma & Biotech edition of the IP Thinktank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com] Highlights this week included: Mircera (Methoxy polyethylene glycol-epoetin beta) - US: Trial judge grants permanent injunction in case relating to recombinant erythropoietin (EPO) patent: Amgen… [read post]
27 Sep 2008, 12:08 am
You can separately subscribe to the Pharma & Biotech edition of the Global week in Review by subscribing by email, or selecting ‘all posts’ or Pharma, Biotech & Chem' for the RSS option at the Subscribe page: [duncanbucknell.com]   Highlights this week included: Canada/Africa: Apotex ships patented AIDS drugs to Rwanda under Canada's Access to Medicines Regime (CAMR) (Managing Intellectual Property) (GenericsWeb) Consolidation in the generic… [read post]
12 Sep 2008, 2:33 pm
: (IP finance), MARQUES international advertising portal goes live: (Class 46)   Global - Patents Using patent landscaping analytics to improve the quality of M & A decisions: a review of Cox Enterprises’ $300M purchase of Adify: (IP Asset Maximiser Blog), Universities reap royalty rewards; investors ignore IP at their peril: (IAM), Top IP-owning nations claim faster patent processing; near harmonisation deal: (Intellectual Property Watch), Bosch, Xerox and Dupont sign up… [read post]
29 Aug 2008, 1:25 pm
– Discussion of IPFrontline.com article ‘Understanding Intellectual Property Value’: (IP finance), How to make sure your IP strategy plan is not doomed to failure: (IP Asset Maximizer Blog) Improve venture capital returns with IP portfolio management: (Ezine @rticles)   Global - Trade Marks / Domain Names / Brands Trade mark strategy – counterintuitive names: (IP Thinktank), ICANN Intellectual Property Constituency paper on sunrise mechanisms for… [read post]
9 Aug 2008, 1:50 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: The end of William Patry’s blog: (Patry Copyright Blog), (Excess Copyright), (Patently-O), (Chicago IP Litigation Blog), (Michael Geist), (The Fire of Genius), (Techdirt), (Patry Copyright Blog), Kitchin J clarifies scope of biotech patents, in particular gene sequence patents: Eli Lilly & Co v Human Genome Sciences:… [read post]
7 Aug 2008, 4:54 am
§ 271(e)(1) states: It shall not be an act of infringement to make, use, offer to sell, or sell within the United States or import into the United States a patented invention . . . solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use or sale of drugs or veterinary biological products. [read post]
2 Aug 2008, 12:54 am
: (Holman’s Biotech IP Blog), Daiichi’s open offer for 20% in Ranbaxy awaits Sebi nod: (GenericsWeb), Australia/India: Strides shows thumbs up for Indian generic industry acquiring controlling interest in Ascent: (Spicy IP), Europe: Significant date ahead for EU Paediatric Regulation: (SPC Blog), India: Grave diggers, ‘immoral’ patent and the National Biotech Regulatory Authority: (Spicy IP), UK: Monster trade mark infringement case: court reveals its… [read post]
24 Jul 2008, 2:15 pm
IN THE UNITED STATES COURT OF APPEALS FOR THE ELEVENTH CIRCUIT'---~F;:U'l";;ED;::---U.S. [read post]
27 Jun 2008, 10:04 am
Porsche AG: (Class 46), WIPO: Yell Limited v Yell.travel: domain name yell.travel to be transferred to Yell Limited: (Class 46), Some see rise in non-traditional trade marks; national registries not yet: (Intellectual Property Watch)   Global - Patents Lower patentability standards – strategic responses: (IP Thinktank), IP Business Congress sees Finnish inventor become a millionaire: (IAM), Ron Slusky: Five prescriptions for effectively analysing an invention and then… [read post]
20 Jun 2008, 8:07 am
: (Spicy IP), Latin America: Merck Serono signs distribution agreement with Bristol-Myers Squibb for portfolio of established pharmaceutical brands in Latin America: (IP tango), US: Biotech industry growth to slow due to funding pressures and competition from biosimilars: (Managing Intellectual Property), US: House Commerce Committee posts responses to its questions on biogenerics; not surprisingly, the views run the gamut: (FDA Law Blog), US: Biosimilar debate heats up at BIO: (Managing… [read post]
13 Jun 2008, 3:40 am
, Schering-Plough Corp – Following dispute over trade dress with Schering-Plough, Fruit of the Earth announces plan to change its package design: (IP Law360), US: Quanta and its impact on biotechnology: (Holman’s Biotech IP Blog), US: BIO files amicus brief asking CAFC to cabin in scope of KSR and hold that its obvious to try dicta does not abrogate the Deuel standard: In re Kubin: (Patently-O), US: StemCells gets patent on enriched central nervous system stem cell and… [read post]
9 May 2008, 10:30 pm
: (Afro-IP), (Managing Intellectual Property), Rwanda: Four years after AIDS drugs bill passed, first low cost meds may head to Rwanda: (GenericsWeb), US: Abbott’s first quarter lobbying tab hits $880,000: (Patent Docs), US: House Bill would expand federal drug pedigree requirements and preempt state requirements: (FDA Law Blog), US: Purchasing Canadian drugs and patent infringement: Litecubes decision: (Patently-O), US: Neuralstem seeks to reopen stayed patent… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in… [read post]
15 Mar 2008, 7:00 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: WIPO Copyright Committee 16th session to discuss Broadcast Treaty, new proposal for exceptions and limitations agreement: (Public Knowledge), (Public Knowledge), (Intellectual Property Watch), (Public Knowledge), (Public Knowledge), (IPwar’s), (Intellectual Property Watch), (KEI), (Public Knowledge), (IP Justice), (IP Justice), (KEI), (KEI),… [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying in 2007: (Patent… [read post]
29 Feb 2008, 8:00 am
– Teva’s opposition proceedings regarding IL 130424 to Pfizer: (IP Factor), Thailand: Thai chief drug price negotiator removed from post: (GenericsWeb), Thailand: Compulsory licences cannot be revoked: (Generic Pharmaceuticals & IP), (more from Generic Pharmaceuticals & IP), UK: Court of Appeal for England and Wales hands down decision in Boehringer Ingelheim KG and Boehringer Ingelheim Pharma KG v Swingward Limited relating to repackaging and… [read post]
22 Feb 2008, 6:00 pm
: (GenericsWeb),US: Dr Robert Shapiro discusses follow-on biologics report: (Patent Docs),US: New report identifies $387 billion in savings from generic biologics: (Holman's Biotech IP Blog),US: Can approval of biogenerics really save money? [read post]
15 Feb 2008, 9:00 am
: (Spicy IP),USD 20 billion going off-patent: (Patent Circle),Canadian Prices Review Board asserts jurisdiction over products sold in US, but imported into Canada under Special Access Program: (Gowlings),Canadian Court of Appeal affirms decision allowing patent-owner to be joined to proceedings: Cobalt v Pfizer and Pharmascience v Pfizer: (Gowlings),PharmaStem appeals stem cell patent: asks for greater deference to patent examiners:… [read post]